Pharmaceutical company AbbVie (<a>NYSE: ABBV</a>) will be reporting earnings this Thursday before market open. Here’s what investors should know. \n\nAbbVie beat analysts’ revenue expectations by 3.3% last quarter, reporting revenues of $13.34 billion, up 8.4% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ constant currency revenue estimates and a decent beat of analysts’ EPS estimates. \n\nIs AbbVie a buy or sell going into earnings? <a>Read our full analysis here, it’s free</a>.\n\nThis quarter, analysts are expecting AbbVie’s revenue to grow 4% year on year to $15.04 billion, in line with the 3.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.91 per share. \n\nAnalysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. AbbVie has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.2% on average. \n\nLooking at AbbVie’s peers in the biotechnology segment, only Incyte has reported results so far. It beat analysts’ revenue estimates by 5.5%, delivering year-on-year sales growth of 16.5%. \n\nRead our full analysis of <a>Incyte’s earnings results here</a>.\n\nInvestors in the biotechnology segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. AbbVie is up 3% during the same time and is heading into earnings with an average analyst price target of $210.08 (compared to the current share price of $191.23).

AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings

Pharmaceutical company AbbVie is set to report Q2 earnings, beating revenue expectations by 3.3% to $13.34 billion, with analysts predicting a 4% year-on-year revenue growth to $15.04 billion. Incyte, a peer in the biotechnology sector, also exceeded revenue estimates. AbbVie's stock is up 3% amid analyst price targets of $210.08.